We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Fortress Biotech

News List

Fortress Biotech Announces Initiation of Phase 3 Studies of CAEL-101 in AL Amyloidosis americanpharmaceuticalreview
September 21, 2020
Fortress Biotech announced Caelum Biosciences, in collaboration with Alexion Pharmaceuticals, has initiated the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 clinical program to evaluate CAEL-101 ...
Fortress Biotech Announces EMA Orphan Drug Designation for Menkes Disease Treatment americanpharmaceuticalreview
August 11, 2020
Fortress Biotech announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products issued a positive opinion on Cyprium Therapeutics’ (Cyprium) application for Orphan Drug Designation for Copper Histidinate ...
Fortress Biotech Forms New Subsidiary contractpharma
January 09, 2017
Caelum Biosciences together with Columbia Univ. to develop novel treatment for AL amyloidosis